Former Official Faults U.S. FDA For Approving Ranbaxy Drugs
This article was originally published in PharmAsia News
Executive Summary
A former U.S. FDA official says the agency should have frozen 18 approvals for generic drugs submitted by Ranbaxy Laboratories during a time it was investigating the Indian firm for false data. Mary Pendergast, a former deputy commissioner and now consultant to pharmaceutical and medical-device makers, said in an interview the agency should not have been approving any of the 18 products knowing it could not be "confident of the accuracy and reliability of the information in the applications." A congressional committee is probing the matter along with the Justice Department, which revealed its doubts about the information in court papers. (Click here for more
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.